Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease
Journal of Biochemical and Molecular Toxicology · 2026
DOI: 10.1002/jbt.71093 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2026. Verfasst von Ashutosh Solanki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, JSS University, Noida, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Flavonoids, Alzheimer Disease, Brain Ischemia, Parkinson Disease. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Icariside II (ICS II), a PDE5 inhibitor, is a flavonoid glycoside and primary metabolite of icariin , derived from the herb Herba epimedii , and exhibits promising neuroprotective potential in various pre‐clinical studies. The current review provides evidence that ICS II shows neuroprotective potential against various neurological disorders, mainly including Alzheimer's disease, Parkinson's disease and Cerebral ischemia through modulating neuroinflammation, oxidative stress, neural apoptosis, neurogenesis, mitochondrial and cognitive dysfunction. It regulates multiple signalling pathways including PI3K/Akt, Keap1/Nrf2, TLR4/MyD88/NF‐κB, cGMP/PKG/CREB, TGFB1/Smad, Wnt/β‐catenin signaling and BDNF/TrkB/CREB. The pre‐clinical evidence suggests that ICS II attenuates oxidative stress through increasing antioxidant enzymes SOD, GSH, catalase, and HO‐1, with decreasing MDA and lipid peroxidation. Neuroinflammation is suppressed by inhibition of pro‐inflammatory cytokines and down‐regulation of IL‐1β, IL‐6, TNF‐α, COX‐2, iNOS levels and up‐regulation of tight‐junction proteins like occludin, claudin‐5, ZO‐1. Apoptosis is regulated via altering PARP, Bcl‐2, Bax/Bcl‐2 ratio and reducing caspase‐3 activation. Mitochondrial dysfunction is ameliorated by restoring Complex I activity and increasing mitofusin‐1/2 expression and reducing mitochondrial fission factors. Collectively, these molecular mechanisms show promise for ICS II as a potential candidate in different in vivo and in vitro studies of neurological disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, JSS University, Noida, Uttar Pradesh, India.
- Anand College of Pharmacy, SGI, Agra, Uttar Pradesh, India.
- Division of Pharmacology, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
ORCID-Profile: Jagrati Jain, Niraj Kumar Singh, Praveen T Krishnamurthy
Zitieren
APA
Solanki, A., Sharma, K., Jain, J., Singh, N. K., & Krishnamurthy, P. T. (2026). Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.71093
Vancouver
Solanki A, Sharma K, Jain J, Singh NK, Krishnamurthy PT. Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease. Journal of Biochemical and Molecular Toxicology. 2026. doi:10.1002/jbt.71093
BibTeX
@article{Solanki2026,
author = {Solanki, Ashutosh and Sharma, Khushi and Jain, Jagrati and Singh, Niraj Kumar and Krishnamurthy, Praveen T},
title = {Icariside II in Neurological Disorders: Mechanistic Insights Into Alzheimer's Disease, Cerebral Ischemia and Parkinson's Disease},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
doi = {10.1002/jbt.71093}
}
EUVIMED